- Home
- VSTM vs ONCY Comparison
VSTM vs ONCY Comparison
Compare VSTM & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | ONCY |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 106.1M |
| IPO Year | 2012 | 1999 |
Fundamental Metrics
Financial Performance| Metric | VSTM | ONCY |
|---|---|---|
| Price | $7.87 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $13.38 | $6.00 |
| AVG Volume (30 Days) | ★ 1.9M | 670.4K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,379,000.00 | N/A |
| Revenue This Year | $208.54 | N/A |
| Revenue Next Year | $251.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.79 | N/A |
| 52 Week Low | $3.46 | $0.33 |
| 52 Week High | $11.25 | $1.51 |
Technical Indicators
Market Signals| Indicator | VSTM | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 35.01 | 46.05 |
| Support Level | $7.59 | $0.94 |
| Resistance Level | $8.23 | $1.06 |
| Average True Range (ATR) | 0.55 | 0.06 |
| MACD | -0.25 | 0.00 |
| Stochastic Oscillator | 9.00 | 35.67 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.